{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:45:25Z","timestamp":1777931125224,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ajo.2015.06.011","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T18:53:31Z","timestamp":1435085611000},"page":"569-580.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Intravitreal Anti\u2013Vascular Endothelial Growth Factor Treatment and the Risk of Thromboembolism"],"prefix":"10.1016","volume":"160","author":[{"given":"Matthew B.","family":"Schlenker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deva","family":"Thiruchelvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald A.","family":"Redelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2015.06.011_bib1","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"issue":"11","key":"10.1016\/j.ajo.2015.06.011_bib2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archopht.121.11.1621","article-title":"Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11","volume":"121","author":"Bressler","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2015.06.011_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"14","key":"10.1016\/j.ajo.2015.06.011_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajo.2015.06.011_bib5","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2015.06.011_bib6","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2015.06.011_bib7","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2015.06.011_bib8","series-title":"Deaths: Preliminary data for 2011. National vital statistics reports; vol. 61 no 6","author":"Hoyert","year":"2012"},{"issue":"6","key":"10.1016\/j.ajo.2015.06.011_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ajo.2015.06.011_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1442-9071.2011.02739.x","article-title":"Intravitreous bevacizumab adult safety data: the evidence so far","volume":"40","author":"Al-Qureshi","year":"2012","journal-title":"Clin Experiment Ophthalmol"},{"issue":"20","key":"10.1016\/j.ajo.2015.06.011_bib11","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMe1103334","article-title":"Bevacizumab versus ranibizumab for AMD","volume":"364","author":"Rosenfeld","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2015.06.011_bib12","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ajo.2015.06.011_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ajo.2014.12.005","article-title":"Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy","volume":"159","author":"Ng","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2015.06.011_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2015.06.011_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajo.2011.05.040","article-title":"Emerging evidence concerning systemic safety of anti-VEGF agents\u2013should ophthalmologists be concerned?","volume":"152","author":"Lim","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2015.06.011_bib16","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.ophtha.2014.05.022","article-title":"Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials","volume":"121","author":"Ueta","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2015.06.011_bib17","unstructured":"Ontario Population Projections Update 2011-2036. Ontario\u00a0Ministry of Finance. Spring 2012. Available at. http:\/\/www.fin.gov.on.ca\/en\/economy\/demographics\/projections\/projections2011-2036.pdf. Accessed September 22, 2014."},{"key":"10.1016\/j.ajo.2015.06.011_bib18","series-title":"The Growing Burden of Heart Disease and Stroke in Canada\u00a02003","year":"2003"},{"issue":"3","key":"10.1016\/j.ajo.2015.06.011_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archophthalmol.2010.19","article-title":"Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis","volume":"128","author":"Campbell","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2015.06.011_bib20","unstructured":"Highlights of Prescribing Information. U.S. BLA (BL125156) Ranibizumab injection. FDA. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/125156lbl.pdf. Accessed September 18, 2014."},{"key":"10.1016\/j.ajo.2015.06.011_bib21","series-title":"The ICES Practice Atlas: Patterns of Health Care in Ontario","first-page":"339","article-title":"A summary of studies on the quality of health care administrative databases in Canada","author":"Williams","year":"1996"},{"issue":"19","key":"10.1016\/j.ajo.2015.06.011_bib22","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.2009.683","article-title":"Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery","volume":"301","author":"Bell","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ajo.2015.06.011_bib23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JGP.0b013e31820d93f9","article-title":"At-fault motor vehicle crash risk in elderly patients treated with antidepressants","volume":"19","author":"Rapoport","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.ajo.2015.06.011_bib24","series-title":"CIHI Data Quality Study of Emergency Department Visits for 2004-2005","year":"2008"},{"issue":"2","key":"10.1016\/j.ajo.2015.06.011_bib25","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.ajo.2015.06.011_bib26","unstructured":"Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study. Institute for Clinical Evaluative Sciences. 2006. Available at, http:\/\/www.ices.on.ca\/\u223c\/media\/Files\/Atlases-Reports\/2006\/CIHI-DAD-a-validation-study\/Full%20report.ashx. Accessed August 19, 2014."},{"key":"10.1016\/j.ajo.2015.06.011_bib27","series-title":"Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files","author":"Wilkins","year":"2009"},{"issue":"3","key":"10.1016\/j.ajo.2015.06.011_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ajo.2015.06.011_bib29","first-page":"e18","article-title":"Accuracy of administrative databases in identifying patients with hypertension","volume":"1","author":"Tu","year":"2007","journal-title":"CORD Conference Proceedings"},{"issue":"8","key":"10.1016\/j.ajo.2015.06.011_bib30","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2012.05.028","article-title":"Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis","volume":"119","author":"Campbell","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2015.06.011_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2015.06.011_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jclinepi.2013.05.003","article-title":"The exposure-crossover design is a new method for studying sustained changes in recurrent events","volume":"66","author":"Redelmeier","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ajo.2015.06.011_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajo.2015.06.011_bib34","series-title":"Time series analysis: forecasting and control","author":"Box","year":"1994"},{"issue":"13","key":"10.1016\/j.ajo.2015.06.011_bib35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMsa1114310","article-title":"Physicians' warnings for unfit drivers and the risk of trauma from road crashes","volume":"367","author":"Redelmeier","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2015.06.011_bib36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jclinepi.2011.09.007","article-title":"Lethal misconceptions: interpretation and bias in studies of traffic deaths","volume":"65","author":"Redelmeier","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ajo.2015.06.011_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"10","key":"10.1016\/j.ajo.2015.06.011_bib38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MLR.0000000000000206","article-title":"The ecological fallacy of the role of age in chronic disease and hospital demand","volume":"52","author":"Whyatt","year":"2014","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.ajo.2015.06.011_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ajo.2015.06.011_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaophthalmol.2013.2597","article-title":"Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008","volume":"131","author":"Zhang","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2015.06.011_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02295996","article-title":"Note on the sampling error of the difference between correlated proportions or percentages","volume":"12","author":"McNemar","year":"1947","journal-title":"Psychometrika"},{"issue":"9","key":"10.1016\/j.ajo.2015.06.011_bib42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1532-5415.2012.04098.x","article-title":"First eye cataract surgery and hospitalization from injuries due to a fall: a population-based study","volume":"60","author":"Meuleners","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ajo.2015.06.011_bib43","unstructured":"Report on the 2008\/09 Ontario Stroke Audit. Registry of the Canadian Stroke Network. Institute for Clinical Evaluative Sciences. 2011. Available at, http:\/\/www.ices.on.ca\/\u223c\/media\/Files\/Atlases-Reports\/2011\/RCSN-2008-09-Ontario-stroke-audit\/Full%20report.ashx. Accessed March 13, 2014."},{"issue":"7","key":"10.1016\/j.ajo.2015.06.011_bib44","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2015.06.011_bib45","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415003645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415003645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:15:02Z","timestamp":1757596502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939415003645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0002939415003645"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2015.06.011","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Anti\u2013Vascular Endothelial Growth Factor Treatment and the Risk of Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2015.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}